HPV vax may cut risk of respiratory papillomatosis recurrences
Patients with recurrent disease and those newly diagnosed had equal benefit post-vaccination, Czech researchers say
The quadrivalent HPV vaccine is associated with a significantly lower risk of recurrent respiratory papillomatosis requiring surgery, results from a small trial show.
The findings also suggest that the earlier that affected patients receive their vaccine, the sooner they may show reduced burden of disease, according to researchers from the Czech Republic.
In their phase-3b non-randomised study, they enrolled 50 adults (median age 41; 78% male) newly diagnosed or recurrent respiratory papillomatosis (RP) to assess the impact of HPV vaccination on recurrences requiring surgical intervention.
Of the 30 patients for whom a biopsy sample was available, all were HPV positive; 80% for HPV-6 and 13% for HPV-11.
